Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8%

Aileron Therapeutics, Inc. (NASDAQ:ALRN - Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 297,800 shares, an increase of 15.8% from the September 15th total of 257,100 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 66,100 shares, the short-interest ratio is currently 4.5 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. University of Texas Texas AM Investment Management Co. bought a new stake in Aileron Therapeutics in the 2nd quarter valued at about $4,925,000. Nantahala Capital Management LLC grew its position in Aileron Therapeutics by 82.1% during the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company's stock worth $1,286,000 after buying an additional 209,367 shares in the last quarter. Warberg Asset Management LLC bought a new position in Aileron Therapeutics during the 2nd quarter worth $86,000. Finally, Texas Capital Bank Wealth Management Services Inc raised its holdings in Aileron Therapeutics by 65.9% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company's stock valued at $174,000 after acquiring an additional 10,398 shares in the last quarter. Institutional investors and hedge funds own 90.89% of the company's stock.

Aileron Therapeutics Stock Down 0.8 %

Shares of NASDAQ ALRN traded down $0.03 during midday trading on Monday, hitting $3.59. 15,496 shares of the company's stock were exchanged, compared to its average volume of 72,106. The firm has a market capitalization of $77.60 million, a PE ratio of -1.13 and a beta of 2.35. Aileron Therapeutics has a 12 month low of $1.01 and a 12 month high of $7.42. The company's 50 day moving average price is $2.81 and its 200 day moving average price is $3.40.

Aileron Therapeutics (NASDAQ:ALRN - Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.20). On average, equities research analysts anticipate that Aileron Therapeutics will post -1.41 EPS for the current year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).